Introduction {#s1}
============

Sarcoidosis is a systemic granulomatous disease of unknown etiology that is characterized by extensive local inflammation and granuloma formation in different organs with an increase in T-helper type 1 (Th1) mediated cytokine production ([@bib20]; [@bib22]; [@bib33]; [@bib44]). Pulmonary involvement in sarcoidosis is the leading cause of morbidity and mortality. In the lungs, the presence of activated macrophages and the expansion of oligoclonal T and B cells suggest **s**ustained activation of inflammatory pathways in this disease ([@bib13]; [@bib22]). Activated macrophages, monocytes, and T cells in sarcoidosis produce a plethora of cytokines including TNF-α, IL-1β, interferon (IFN) gamma, IL-17, and others ([@bib12]; [@bib35]; [@bib44]; [@bib53]).

Previously, we have shown that sarcoidosis bronchoalveolar lavage (BAL) cells and alveolar macrophages (AMs), unlike those from healthy controls, exhibit high constitutively active p38 and lack dual specificity phosphatase (DUSP1 or MKP-1). The sustained p38 activation directly controls expression of several cytokines in sarcoidosis AMs and monocytes and the modulation of p38 regulates T cell responses ([@bib44]; [@bib53]). Recently, we performed RNA-sequencing (RNA-seq) in sarcoidosis monocytes and identified altered gene expression profiles and cellular pathways ([@bib54]). These were: metabolic including glycolysis and lipolysis, phagocytosis, inflammation, oxidative phosphorylation, and HIF signaling pathways ([@bib54]). Among differentially expressed genes in sarcoidosis monocytes, we found a large number of genes containing hypoxia response elements (HREs) in their regulatory regions and, by pathway analysis, enrichment of hypoxia inducible factor signaling pathways. Furthermore, in an independent study applying ^1^H nuclear magnetic resonance (NMR)-based analysis, we identified metabolic and mitochondrial alterations in sarcoidosis ([@bib15]). Based on these observations, we hypothesize that HIF-isoform expression plays an important role in the maintenance of inflammation ([@bib44]; [@bib53]), metabolic imbalance, and mitochondrial dysfunction in sarcoidosis ([@bib15]).

The oxygen-sensitive transcription factors HIF-1α and HIF-2α are key transcriptional regulators of hypoxia-associated genes to adapt to decreased availability of O~2~ ([@bib51]; [@bib65]). In the presence of O~2~, cytosolic HIF-α isoforms are hydroxylated by prolyl-hydroxylases (PHD) through an iron dependent mechanism, which prevents heterodimerization with HIF-1β (ARNT) and consequent nuclear translocation as an active transcription factor ([@bib40]; [@bib50]; [@bib51]). HIF transcription factors alter the expression of various genes involved in metabolism, cell differentiation, proliferation, and angiogenesis in hypoxic tissues. Although the role of HIF-α isoforms in hypoxia and cancer is well studied, there is a knowledge gap regarding their role in regulating immune cells under normoxic conditions. The role of HIF-1α in sarcoidosis has not been studied. In the current study, we applied a combination of transcriptional and functional approaches to investigate the role of HIF-1α in mediating the inflammatory immune response in AMs, monocytes, and PBMCs of sarcoidosis patients as compared to healthy controls. Because sarcoidosis predominantly affects the lungs, we carried out the functional studies using AMs to determine the lung immune responses, while monocytes and PBMCs were used to assess peripheral immunity. Under normoxic conditions we found enhanced expression and activity of HIF-1α in sarcoidosis AMs and monocytes. Furthermore, HIF-1α expression was directly correlated with IL-1β production in AMs and PBMCs. Down regulation of HIF-1α expression via short interfering RNA (siRNA) decreased IL-1β in sarcoidosis AMs, while decreased HIF-1α expression in PBMCs decreased IL-1β and IL-17 in response to anti-CD3 challenge.

Results {#s2}
=======

RNA-seq data of sarcoidosis monocytes identifies enrichment of the HIF-1α signaling pathway {#s2-1}
-------------------------------------------------------------------------------------------

Patients ([Table 1](#table1){ref-type="table"} and Materials and methods) were ambulatory outpatients who were not hypoxic. Differentially expressed (DE) genes between sarcoidosis monocytes and healthy monocytes previously determined ([@bib54]) were subjected to pathway analysis. The pathway analysis showed impaction of metabolic pathways, including oxidative phosphorylation, purine and pyruvate metabolism in sarcoidosis. Because most of genes in these pathways showed the presence of hypoxia response elements (HREs), we further focused on interrogation of the HIF-pathway. [Figure 1A](#fig1){ref-type="fig"} shows the heat map of HIF signaling genes in monocytes. There are clear differences in the intensity and expression of genes related to the HIF pathway in monocytes of healthy controls and sarcoidosis subjects. Next, we compared the expression of selected genes related to HIF transcription factor activity. The transcription factor aryl hydrocarbon receptor nuclear translocator (ARNT, also known as HIF-1β) heterodimerizes with HIF-1α to form a transcriptional active complex ([@bib68]). The gene count between sarcoidosis and healthy control subjects demonstrate significantly higher ARNT gene expression in sarcoidosis monocytes ([Figure 1B](#fig1){ref-type="fig"}). Endothelial PAS domain protein 1 (EPAS1), also known as HIF-2α, is a hypoxia inducible transcription factor ([@bib18]; [@bib60]). The EPAS1 gene count between sarcoidosis and healthy control subjects demonstrates significantly higher EPAS1 expression in sarcoidosis monocytes ([Figure 1C](#fig1){ref-type="fig"}). EP300 is a co-activator important for transcriptional activity of HIFs ([@bib40]). Similarly, we found higher p300 gene expression in sarcoidosis monocytes as compared to healthy controls ([Figure 1D](#fig1){ref-type="fig"}). However, there were no differences in HIF-1α gene transcripts between the two groups.

![Enrichment of HIF-1α signaling pathways and related genes in sarcoidosis.\
Pathway analysis of DE genes between sarcoidosis versus healthy control monocytes was done using the iPathwayGuide tool. (**A**) Heatmap of genes involved in HIF-1α signaling between sarcoid and healthy control monocytes. Dendrograms according to means identifying genes levels in the heatmap show two distinct clusters. Green shading represents high expression and red shading represents low expression. (**B--D**) Data presented as box plots of gene counts corrected based on an FDR of 0.05. Boxplots for gene expression in monocytes are shown for ARNT (**B**), EPAS1 (**C**), and EP300 (**D**).\
10.7554/eLife.44519.004Figure 1---source data 1.RNA-seq data of Sarcoid vs Healthy monocytes.](elife-44519-fig1){#fig1}

10.7554/eLife.44519.005

###### Subject Demographics.

  -----------------------------------------------------------------
  Characteristic                Patients      Control subjects   
  ----------------------------- ------------- ------------------ --
  Age, y                        27.7 ± 11.4   28 ± 8.4           

  BMI                           29 ± 10.4     28 ± 3.6           

  Gender, N (%)                                                  

  Female                        35 (77)       16(70)             

  Male                          10 (23)       7 (30)             

  Race, N (%)                                                    

  African American              51 (100)      15 (75)            

  Caucasian                     0 (0)         5 (25)             

  CXR stage, N (%)                                               

  0                             0 (0)         NA                 

  1                             5 (11)        NA                 

  2                             30 (66)       NA                 

  3\                            10 (22)\      NA\                
  O~2~ saturation at Room Air   96--100       97--100            

  Organ Involvements, N (%)                                      

  Neuro-ophtalmologic           8 (17)        NA                 

  Lung                          43 (95)       NA                 

  Skin                          12 (26)       NA                 

  Multiorgan                    26 (57)       NA                 

  PPD                           Negative      NA                 
  -----------------------------------------------------------------

Definition of abbreviations: BMI = body mass index, CXR = chest X-ray, NA = not applicable, PPD = purified protein derivative.

Increased protein expression of HIF-α isoforms in sarcoidosis {#s2-2}
-------------------------------------------------------------

Since HIF-1α is known to be predominantly regulated through modification of its protein stability ([@bib27]; [@bib47]), we evaluated HIF-1α and HIF-2α protein abundance in AMs and monocytes of sarcoidosis patients, isolated as described in Materials and methods. AMs or monocytes were cultured ex vivo under normoxic conditions. Western analysis of cell lysates probed with antibody against HIF-1α showed increased HIF-1α protein expression in sarcoidosis AMs and monocytes ([Figure 2A and B](#fig2){ref-type="fig"}). Similar results were seen for HIF-2α protein expression ([Figure 2C and D](#fig2){ref-type="fig"}). Since HIFα heterodimerizes with ARNT (also known as HIF-1β), translocates to the nucleus, and recruits transcriptional coactivator p300 to transactivate target genes containing hypoxia-responsive elements (HREs) ([@bib50]; [@bib55]; [@bib56]), we also examined their protein expression. Sarcoidosis AMs also show a higher expression of ARNT ([Figure 2E and F](#fig2){ref-type="fig"}) and p300 ([Figure 2E and G](#fig2){ref-type="fig"}). Similarly, we evaluated the HIF-1α protein abundance in isolated monocytes from sarcoidosis subjects and healthy controls and found significantly higher HIF-1α expression ([Figure 2H and I](#fig2){ref-type="fig"}). However, in contrast to increased HIF-2α gene transcripts, we did not detect HIF-2α in either sarcoidosis or control monocytes at the protein level. Because the lack of detection could have been due to low protein abundance in monocytes or lower sensitivity of antibody epitope, we compared the HIF-1α and −2α expression by flow cytometry. [Figure 2J](#fig2){ref-type="fig"} shows FSC-A/SSC-A gating. FACS analysis of PBMCs double stained for CD14 and HIF-1α or HIF-2α shows that in healthy controls 5--9% of PBMCs are CD14^+^HIF-1α^+^, whereas in sarcoidosis 20% to 35% of PBMCs are CD14^+^ HIF-1α^+^. Analysis of CD14^+^ monocytes based on the expression of HIF-1α shows 25--60% HIF-1α^+^ CD14^+^ monocytes in controls, whereas in sarcoidosis HIF-1α^+^ CD14^+^ monocytes are 64--96% (K). Interestingly, in healthy controls 0--0.1% of PBMCs are CD14^+^ HIF-2α^+^, whereas in sarcoidosis 1--3% of PBMCs are CD14^+^ HIF-2α^+^. It shows that in healthy controls the percentage of HIF-2α^+^ CD14^+^ monocytes is negligible, whereas in sarcoidosis there is higher percentage of HIF-2α^+^ CD14^+^monocytes (5--9%) ([Figure 2L](#fig2){ref-type="fig"}). Thus, these results show that sarcoidosis AMs and peripheral monocytes exhibit increased expression of HIF isoforms compared to healthy controls. These data suggest a different protein expression profile of HIF-2α in lung macrophages versus peripheral monocytes with low abundance in monocytes versus AMs.

![Increased expression of HIF-1α, HIF-2α, ARNT, and p300 in sarcoidosis.\
Whole cell extracts of AMs and monocytes were prepared and subjected to SDS-PAGE and western blot analysis using specific antibodies for HIF-1α, HIF-2α, ARNT, and p300. Equal loading was confirmed using antibodies against β-actin. Densitometry analysis is expressed as fold increase of the ratio of specific protein/β-actin. Sarcoid AMs exhibited higher HIF-1α expression (**A and B**) as compared to healthy controls. Sarcoid AMs expressed higher HIF-2α (**C and D**), ARNT (**E and F**) and p300 (**E and G**) as compared to healthy controls. Sarcoid monocytes exhibited higher HIF-1α expression (**H and I**) as compared to healthy controls. Representative blots for AMs and monocytes are shown out of a total of 10 patients and seven controls. Flow cytometry of PBMCs double stained for CD14^+^HIF-1α + and CD14^+^HIF-2α^+^ (**J and K**). PBMCs of healthy controls and sarcoid were stained with CD14-PerCPCy5.5, HIF-1α or CD14-PerCPCy5.5, HIF-2α primary antibodies followed by Alexa 488 secondary antibody and analyzed by flow cytometry using Flow-jo software. [Figure 2J](#fig2){ref-type="fig"} shows FSC-A/SSC-A gating. In healthy controls, 5--9% of PBMCs were CD14^+^HIF-1α^+^ whereas in sarcoidosis 20% to 35% of PBMCs were CD14^+^HIF-1α^+^ (**K**). HIF-2α expression was negligible in control PBMCs whereas 3% of sarcoid PBMCs were CD14^+^HIF-2α^+^ (**L**). Representative scatter plots from 4 patients and three controls are shown.](elife-44519-fig2){#fig2}

Confocal microscopy of sarcoidosis AMs and immunohistochemistry of sarcoidosis tissues confirmed increased HIF-1α expression and its nuclear accumulation {#s2-3}
---------------------------------------------------------------------------------------------------------------------------------------------------------

To further confirm increased expression of HIF-1α protein in sarcoidosis and to determine whether HIF-1α accumulates in the nucleus, we immunostained AMs using specific an antibody against HIF-1α. Images were analyzed by immunofluorescent microscopy (AX10, Zeiss). We quantitated the percentage of cells showing HIF-1α expression ([Figure 3A and B](#fig3){ref-type="fig"}) in sarcoidosis. The staining is representative of one out of the five patients. It shows that about 60--90% of AMs express HIF-1α. Images ([Figure 3C--H](#fig3){ref-type="fig"}) were analyzed by confocal laser scanning microscopy (CLSM-310, Zeiss). Confocal microscopy images show nuclei stained with DAPI (blue) in a single AM (C) and a multinucleated giant cell (D), nuclear and cytoplasmic accumulation of HIF-1α in green (E and F), overlay image shows nuclear co-localization of HIF-1α (G and H).We saw enhanced expression and accumulation of HIF-1α in the cytoplasm and nuclei of sarcoidosis AMs, both in a single AM ([Figure 3E](#fig3){ref-type="fig"}) and in a multinucleated giant cell ([Figure 3F](#fig3){ref-type="fig"}) that are known to be characteristic cells in sarcoidosis granuloma. HIF-1α is highly expressed and overlay images show that HIF-1α accumulates in nuclei ([Figure 3G and H](#fig3){ref-type="fig"}) as compared to cytoplasm. To further explore the expression seen in sarcoidosis AMs, we assessed the presence of HIF-1α in lung biopsies of patients with sarcoidosis. Positive immunostaining was seen in multinucleated giant cells of granulomas as well as macrophages ([Figure 3I and J](#fig3){ref-type="fig"}, thick arrow), whereas fibroblasts and normal lungs lack HIF-1α expression. Negative staining was done by using isotype control antibody ([Figure 3K](#fig3){ref-type="fig"}). Similarly, we observed increased HIF-1α immunostaining signal in sarcoidosis liver and skin tissue samples. These results further confirmed that HIF-1α accumulates in sarcoidosis granulomatous tissues.

![Increased HIF-1α expression in sarcoidosis AMs and granulomatous sarcoidosis lung tissue.\
Immunofluorescence staining of sarcoidosis AMs showing presence of HIF-1α in the cytoplasm and nuclei. AMs (1 × 10^5^) were allowed to adhere on chamber slides overnight. The cells were washed with PBST and fixed with 3.7% paraformaldehyde. Cells were permeabilized with 0.1% Triton X-100, blocked (10% FCS), and then incubated with anti-HIF-1α antibody overnight at 4°C. The secondary antibody was Alexa-fluor 488 - conjugated goat anti-rabbit antibody. Images were analyzed by immunofluorescent microscopy (AX10, Zeiss). Images show nuclei staining of AMs (**A**), overlay image shows nuclear and cytoplasmic co-localization of HIF-1α (**Β**). Confocal laser scanning microscopy (CLSM-310, Zeiss) images show nuclei stained with DAPI (blue) in a single AM (**C**) and a multinucleated giant cell (**D**), nuclear and cytoplasmic accumulation of HIF-1α in green (**E and F**), overlay image shows nuclear co-localization of HIF-1α (**G and H**). The images are representative from two patients out of total of 5 patients. The photomicrographs represent in situ immunohistochemistry performed on lung tissues. H and E staining of tissue obtained from transbronchial biopsy (**I**) 100X, HIF-1α immunostaining (**J**), negative staining using isotype control antibody (**K**). The brown color represents an area of precipitate formed by a chromogenic substrate that is transformed by an enzymatic label conjugated to the antibody that has bound to the HIF-1α antigen. Note that the intensity of the staining is most pronounced in the histiocytic cells (i.e., AMs and the multinucleated giant cells, thick arrow), and is not identified in the surrounding alveoli (thin arrow). The immunohistochemistry images are representative from one patient out of total of 5 patients.](elife-44519-fig3){#fig3}

Increased Glut1, pro-IL-1β levels and IL-1β, IL-1Ra production in sarcoid AMs and monocytes {#s2-4}
-------------------------------------------------------------------------------------------

HIF-1α is a critical transcription factor regulating metabolic reprogramming during inflammation, in part through upregulation of the *SLC2A1* gene encoding glucose transporter (Glut)1 ([@bib5]). HIF-1α and Glut1 upregulation contribute to production of several pro-inflammatory cytokines including IL-1β ([@bib55]; [@bib56]; [@bib59]). Therefore, we evaluated the expression of Glut1 and pro-IL-1β at baseline in AMs and monocytes from sarcoidosis and control subjects. Sarcoidosis AMs exhibited a variable amount of Glut1 and pro-IL-1β (18/18 patients) but only 1 out of 10 healthy controls showed expression ([Figure 4A and B](#fig4){ref-type="fig"}). We found similar results for pro-IL-1β in monocytes ([Figure 4C and D](#fig4){ref-type="fig"}). Furthermore, increased pro-IL-1β expression directly correlated with Glut1 and HIF-1α expression in sarcoidosis AMs ([Figure 4E](#fig4){ref-type="fig"}). To determine whether increased pro-IL-1β expression in sarcoidosis leads to released IL-1β, we measured secreted IL-1β in the conditioned media of AMs and monocytes cultured in the absence or presence of LPS via ELISA. The results showed that unstimulated and LPS-stimulated cultured sarcoidosis AMs and monocytes secrete higher IL-1β as compared to healthy controls ([Figure 4F and G](#fig4){ref-type="fig"}). These data suggest that increased expression of HIF-1α leads to increased IL-1β production in sarcoidosis patients. The interleukin one receptor antagonist (IL-1Ra) is mainly secreted by monocytes, macrophages, and neutrophils. IL-1Ra (IL-1RII) competitively binds to IL-1β and forms a nonsignaling complex IL-1Ra to the surface receptors for IL-1β and inhibits the effect of IL-1β on cells ([@bib2]; [@bib23]). Since the sarcoidosis AMs produced significantly high levels of IL-1β, we assessed the conditioned media for the secreted IL-1Ra. [Figure 4H](#fig4){ref-type="fig"} shows that sarcoidosis AMs produced significantly high levels of IL-1Ra as compared to control AMs. Similarly, sarcoidosis PBMCs ([Figure 4I](#fig4){ref-type="fig"}) produced high levels of IL-1Ra as compared to control PBMCs.

![Increased Glut1, pro-IL-1β expression and IL-1β, IL-1Ra in sarcoidosis.\
AMs or monocytes from sarcoid subjects and controls were cultured overnight. Whole cell extracts were prepared, and culture supernatants were collected to measure IL-1β. Whole cell extracts were subjected to SDS-PAGE and western blot analysis using specific antibodies for Glut1, pro- IL-1β and HIF-1α. Equal loading was confirmed using β-actin antibody. Densitometry analysis is expressed as fold increase of the ratio of specific protein/β-actin. IL-1β was measured in culture supernatants via ELISA. Sarcoidosis AMs (n = 18) exhibited significantly higher expression of Glut1 and pro- IL-1β as compared to control subjects (n = 10) (**A and B**). The western blot and densitometric results (black bars for pro- IL-1β and grey bars for Glut1) are representative from three patients out of total of 18 patients and three controls out of total of 10 control subjects. Monocytes from sarcoid subjects also exhibited significantly higher pro-IL-1β as compared to controls (**C and D**). The western blot and densitometric results are representative from three patients out of total of 10 patients and 3 controls out of 10 control subjects. These data indicate that sarcoid AMs exhibit higher pro-IL-1β at baseline and this highly correlates with HIF-1α expression (**E**). Sarcoidosis AMs (**F**) and monocytes (**G**) produced significantly higher IL-1β cytokine at baseline and after LPS-stimulation as compared to healthy controls. Sarcoidosis AMs (**H**) and PBMCs (**I**) produced significantly higher IL-1Ra at baseline as compared to healthy controls. ELISA results represent mean ± SEM from 10 patients and 10 controls (4F and 4G), 10 patients and five controls (4H and 4I). \*, p \< 0.05 and was considered significant.\
10.7554/eLife.44519.010Figure 4---source data 1.IL-1β and IL-1Ra production in sarcoid AMs,monocytes or PBMCs.](elife-44519-fig4){#fig4}

Targeted downregulation of HIF-1α decreases IL-1β production in sarcoidosis AMs {#s2-5}
-------------------------------------------------------------------------------

IL-1β is regulated at the transcriptional level through expression of several transcription factors including Signal Transducer and Activator of Transcription (STAT) 3, HIF-1α, and others ([@bib48]; [@bib56]). To determine the relative contribution of increased HIF-1α in IL-1β production in sarcoidosis AMs, we transiently transfected sarcoidosis AMs with either non-targeted siRNA or HIF-1α targeted siRNA. After 24 hr of transfection, cells were treated with LPS (100 ng/mL). Targeted downregulation of HIF-1α via siRNA of sarcoidosis AMs led to a significant reduction (about 50%) in HIF-1α ([Figure 5A and B](#fig5){ref-type="fig"}) and pro-IL-1β ([Figure 5C and D](#fig5){ref-type="fig"}) protein expression. To determine the specificity of targeted downregulation of HIF-1α on other cytokines, we assessed the conditioned medium for IL-1β and IL-10 production and found significantly decreased IL-1β production ([Figure 5E](#fig5){ref-type="fig"}). However, HIF-1α inhibition did not inhibit IL-10 production ([Figure 5F](#fig5){ref-type="fig"}).

![HIF-1α downregulation via siRNA decreases IL-1β production in sarcoid AMs.\
AMs from sarcoidosis subjects were transiently transfected with nonsense vector (NS siRNA, 200 pM) or targeted HIF-1α siRNA (200 pM, Thermofisher-Scientific). After 24 hr of transfection, cells were activated with LPS (100 ng/mL) for 3 hr. Whole cell lysates obtained after 3 hr of activation were subjected to immunoblotting to assess the HIF-1α and pro- IL-1β expression. Values were normalized to β-actin and are shown as relative expression to NS siRNA control. Conditioned media were collected after 24 hr and were assessed for different cytokines. HIF-1α siRNA significantly reduced both HIF-1α and pro-IL-1β protein in AMs (**A--D**). HIF-1α siRNA significantly inhibited IL-1β (**E**) but had no inhibitory effect on IL-10 (**F**) in AMs. Western blot data presented is a representative of four independent experiments. ELISA results represent mean ± SEM from four different experiments. \*, p \< 0.05 and was considered significant.\
10.7554/eLife.44519.012Figure 5---source data 1.Effect of downregulation of HIF-1α via siRNA on IL-1β and IL-10 production in sarcoid AMs.](elife-44519-fig5){#fig5}

Downregulation of HIF-1α modulates cytokine profiles in sarcoidosis PBMCs in response to LPS and anti-CD3 {#s2-6}
---------------------------------------------------------------------------------------------------------

Similar to AMs, the targeted down regulation of HIF-1α in sarcoidosis PBMCs resulted in decreased production of IL-1β in response to LPS ([Figure 6A](#fig6){ref-type="fig"}); the effect of HIF-1α inhibition was specific for IL-1β since there was no significant effect on IL-10 production ([Figure 6B](#fig6){ref-type="fig"}). These results clearly show that HIF-1α expression regulates IL-1β production in sarcoidosis AMs and PBMCs.

![Downregulation of HIF-1α reduces the production of IL-1β, IL-17, and IL-6 in sarcoid PBMCs.\
PBMCs were transiently transfected with nonsense vector (NS siRNA, 200 pM) or targeted HIF-1α siRNA (200 pM, Thermofisher-Scientific). After 24 hr of transfection, cells were activated with either LPS (100 ng/mL) or anti-CD3 (1 μg/mL) in the presence of rhIL-2 (10 ng/mL). Conditioned media were collected after 24 hr (stimulated with LPS) or after 72 hr (stimulated with anti-CD3) and were assessed for cytokines via ELISA. HIF-1α siRNA significantly inhibited IL-1β (**A**) but had no inhibitory effect on IL-10 (**B**). The conditioned media of anti-CD3 stimulated sarcoidosis PBMCs (n = 11) or healthy control PBMCs (n = 10) show that sarcoidosis PBMCs produced significantly higher IL-1β (**C**) and IL-17 (**D**) as compared to healthy control PBMCs. HIF-1α siRNA significantly inhibited IL-1β (**E**), IL-17 (**F**) and IL-6 (**G**). HIF-1α siRNA did not inhibit IFN-γ (**H**), or IL-10 (**I**). ELISA results obtained from siRNA experiments represent mean ± SEM of four different experiments. \*, p \< 0.05 and was considered significant.\
10.7554/eLife.44519.014Figure 6---source data 1.Effect of downregulation of HIF-1α via siRNA on IL-1β , IL-10, IL-17,IL-6 and IFN-γ production in sarcoid PBMCs.](elife-44519-fig6){#fig6}

Recent work has shown that the HIF transcription factors are key elements in the control of immune cell metabolism and function in macrophages, B-cells, and T-cells ([@bib40]; [@bib65]). T helper 17 cells (Th17) represent a lineage of effector T cells critical in host defense and autoimmunity. It is has been shown that Th1 and Th17 cells contribute to sarcoidosis pathology ([@bib43]). Based on this, we hypothesize that the HIF-1α inhibition may also modulate IL-1β and IL-17 production in response to anti-CD3 challenge. First, we assessed the effect of anti-CD3 activation on the production of IL-1β and IL-17 in healthy controls and sarcoidosis PBMCs. PBMCs were treated with anti-CD3 for 24 hr and the conditioned media were assessed for IL-1β and IL-17 production. Sarcoidosis PBMCS were seen to produce significantly higher levels of IL-1β ([Figure 6C](#fig6){ref-type="fig"}) and IL-17 ([Figure 6D](#fig6){ref-type="fig"}). To investigate the contribution of HIF-1α in Th1/Th17 cytokine production, we investigated the effect of targeted downregulation of HIF-1α in PBMCs in response to anti-CD3 challenge on the production of various inflammatory cytokines. Inhibition of HIF-1α by siRNA significantly decreased the production of anti-CD3 induced IL-1β ([Figure 6E](#fig6){ref-type="fig"}), IL-17 ([Figure 6F](#fig6){ref-type="fig"}), and IL-6 ([Figure 6G](#fig6){ref-type="fig"}). However, inhibition of HIF-1α did not decrease IFN-γ ([Figure 6H](#fig6){ref-type="fig"}) and IL-10 ([Figure 6I](#fig6){ref-type="fig"}) production. These results suggest that HIF-1α specifically regulates IL-1β and IL-17 in sarcoidosis.

Pharmacological HIF-1α inhibition decreases the percentage of activated T-cells and cytokines in sarcoidosis PBMCs in response to anti-CD3 {#s2-7}
------------------------------------------------------------------------------------------------------------------------------------------

To confirm our results, we used echinomycin, a small molecule inhibitor of HIF-1α that has been shown to inhibit HIF-1α DNA binding activity ([@bib58]; [@bib63]). We evaluated the effect of echinomycin HIF-1α inhibition on anti-CD3-induced IL-1β and IL-17 production and T cell activation in sarcoid PBMCs. To do so, cultured sarcoidosis PBMCs were pre-treated with echinomycin in vitro, then activated with anti-CD3 in the presence of rIL-2, followed by determination of activated CD4^+^CD25^+^ T-cells by flow cytometry and measurement of cytokines by ELISA. Our results showed that PBMCs of patients with sarcoidosis (n = 23) exhibit higher expression for activated CD4^+^CD25^+^T cells (mean ± SEM, 11.08 ± 5.32% as compared to healthy (n = 7) controls (mean ± SEM, 5.16 ± 2.71%, p \< 0.05). [Figure 7A](#fig7){ref-type="fig"} shows that PBMCs of a patient with sarcoidosis exhibited higher expression for activated CD4^+^CD25^+^T cells (10%), further increasing to 50% in response to anti-CD3 stimulation ([Figure 7B](#fig7){ref-type="fig"}). Pre-treatment of PBMCs with echinomycin decreased the number of activated T cells (3%) at base line ([Figure 7C](#fig7){ref-type="fig"}) and in response to anti-CD3 stimulation to 15% ([Figure 7D](#fig7){ref-type="fig"}). Furthermore, pretreatment with echinomycin significantly decreased both baseline and anti-CD3 induced IL-1β production ([Figure 7E](#fig7){ref-type="fig"}). Similarly, pretreatment with echinomycin significantly decreased anti-CD3 induced IL-17 ([Figure 7F](#fig7){ref-type="fig"}) and IL-6 ([Figure 7G](#fig7){ref-type="fig"}) production in sarcoidosis PBMCs.

![HIF-1α inhibition reduces the percentage of activated CD4 +CD25+cells in anti-CD3 stimulated sarcoid PBMCs and the production of IL-1β, IL-17, and IFN-γ.\
PBMCs of sarcoid subjects were pretreated with echinomycin (HIF-1α inhibitor, 10 nM) for 30 min and were stimulated with anti-CD3 (1 μg/mL) in the presence of rhIL-2 (10 ng/mL) for 72 hr. Cells were harvested after 72 hr of culture and immunostained with fluorescein conjugated antibodies CD4 and CD25 and analyzed by flow cytometry using Flow-jo software. (**A--D**) Representative scatter plots show FACS analysis of CD4 and CD25 expression of sarcoidosis PBMCs. The percentage of CD4 and CD25 double positive, representing activated T-cells, were 10% in untreated PBMCs (**A**). In sarcoidosis PBMCs stimulated with anti-CD3 the percentage of CD4 and CD25 double positive T-cells increased to 50% (**B**). Sarcoidosis PBMCs cultured in the presence of echinomycin for 72 hr. The percentage of CD4 and CD25 double positive cells decreased from 10% to 3% (**C**). Sarcoidosis PBMCs were stimulated with anti-CD3 in the presence of echinomycin. The percentage of activated T-cells decreased from 50% after anti-CD3 challenge to 15% in the presence of echinomycin (**D**). Data presented is a representative plot of 5 independent experiments. The conditioned medium was assessed for IL-1β, IL-17 and IFN-γ using ELISA. Echinomycin significantly inhibited anti-CD3-induced IL-1β (**E**), IL-17 (**F**) and IFN-γ (**G**). Data represent mean ± SEM from six different experiments. \*, p \< 0.05 and was considered significant.\
10.7554/eLife.44519.016Figure 7---source data 1.HIF-1α inhibition reduces the production of IL-1β, IL-17, and IFN-γ in anti-CD3 stimulated sarcoid PBMCs.](elife-44519-fig7){#fig7}

Chloroquine modifies LAMP2, HIF-1α protein expression and inhibits IL-1 β and IL-17 production in sarcoidosis {#s2-8}
-------------------------------------------------------------------------------------------------------------

Chloroquine (CHQ) is an anti-malarial drug and remains an integral treatment for systemic inflammatory diseases such as systemic lupus erythematosus and sarcoidosis ([@bib29]; [@bib34]). CHQ inhibits lysosomal degradation/autophagy either by altering lysosomal acidification or inhibiting the levels of lysosomal associated proteins (LAMP) ([@bib17]; [@bib31]; [@bib46]). We hypothesized that CHQ modulates LAMP2, HIF-1α, and HIF-2α levels and cytokine production in sarcoidosis AMs and PBMCs. To examine this hypothesis, isolated AMs were pre-treated with CHQ and then activated with LPS. Interestingly, CHQ decreased LAMP2 levels and both HIF-1α (by approximately 50%) and HIF-2α protein expression (by approximately 65%) in sarcoidosis AMs after LPS stimulation ([Figure 8A--D](#fig8){ref-type="fig"}). Furthermore, CHQ significantly decreased (70%) the expression of pro-IL-1β ([Figure 8D and E](#fig8){ref-type="fig"}). Similarly, measurement of released IL-1β in conditioned medium was significantly decreased both at baseline and in response to LPS stimulation ([Figure 8F](#fig8){ref-type="fig"}). To assess the effect of CHQ on IL-1β and IL-17 production by sarcoidosis PBMCs, cultured PBMCs were pre-treated with CHQ in vitro and then activated with anti-CD3. CHQ significantly decreased anti-CD3 induced IL-1β ([Figure 8G](#fig8){ref-type="fig"}) and IL-17 ([Figure 8H](#fig8){ref-type="fig"}) production in sarcoidosis PBMCs (p \< 0.05).

![Chloroquine (CHQ) decreases LAMP2, HIF-α, IL-1 β, and IL-17 production in sarcoidosis.\
Sarcoidosis AMs were pretreated with CHQ (100 µM) for 30 minutes and activated with LPS (100 ng/mL) for 3 hours. Whole cell lysates obtained after 3 hours of activation were subjected to immunoblotting to assess the LAMP2, HIF-1α, HIF-2α, and pro-IL-1β expression. Values were normalized to β-actin and are shown as relative expression to untreated cells. Densitometry analysis is expressed as fold increase of the ratio of specific protein/ β-actin. Culture supernatants were assessed for IL-1β via ELISA. CHQ significantly inhibited LAMP2 (50%) at baseline and both HIF-1α (50%) and HIF-2α (50%) protein expression in response to LPS challenge (**A-D**). CHQ significantly inhibited pro-IL-1β (70%) protein expression in response to LPS treatment (**E and F**) and significantly inhibited IL-1β production both at baseline and in response to LPS (**G**). Sarcoid PBMCs were pretreated with CHQ (100 µM) for 30 min and activated with anti-CD3 (1 µg/mL) in the presence of rhIL-2 (10 ng/mL). Conditioned media were collected after 72 hours and were assessed for IL-1 β and IL-17 via ELISA. CHQ significantly inhibited anti-CD3 induced IL-1β (**H**) and IL-17 (**I**) production. Western blot data presented is representative of five independent experiments. ELISA results represent mean ± SEM from five different experiments. \*, p \< 0.05 and was considered significant.\
10.7554/eLife.44519.018Figure 8---source data 1.Chloroquine (CHQ) decreases IL-1 β and IL-17 production in sarcoidosis..](elife-44519-fig8){#fig8}

Discussion {#s3}
==========

Sarcoidosis is a chronic granulomatous disease with aberrant immune response to undefined environmental or infectious triggers ([@bib22]). How specific antigens lead to a sustained granulomatous inflammation in sarcoidosis is largely unknown. Our novel RNA-seq data showed aberrant metabolic pathways and enrichment of DE genes for HIF pathways in monocytes of sarcoidosis patients ([@bib54]), confirming our previous metabolomics data showing aberrant metabolic pathways including increased glycolysis and malfunctional tricarboxylic acid (TCA) cycle in sarcoidosis ([@bib15]; [@bib54]). In the current study, we investigated the role of HIF-isoforms in sarcoid alveolar macrophages and blood monocytes as well as PBMCs. Alveolar macrophages and monocytes have a central role in the maintenance of immunological homeostasis in response to pathogens providing an important host-defense ([@bib1]). In sarcoidosis, both cell types are in an activated state and produce spontaneous ex vivo cytokines and chemokines including, IL-1β, TNF-α, IL-6, IL-18, and others ([@bib16]; [@bib35]; [@bib44]; [@bib45]). Our current study confirms our previous findings that IL-1β plays an important role in sarcoidosis ([@bib44]; [@bib53]). In addition, we find increased IL-1Ra in sarcoidosis AMs and PBMCs, suggesting activation of the IL-1 pathway. IL-1Ra is a member of the IL-1 family, whose production is stimulated by many substances including cytokines and bacterial or viral components; it has been suggested to act as a decoy receptor and is a natural inhibitor for the biologically active IL-1β ([@bib25]); ([@bib2]; [@bib49]). In several inflammatory diseases, including lupus and Crohn\'s disease (CD), elevated IL-1β production is associated with IL-1Ra ([@bib8]). Our data are in line with previous studies showing increased IL-1Ra in sarcoidosis ([@bib32]; [@bib45]). Further studies need to delineate the clinical role of IL-1Ra in sarcoidosis.

Here, we show that sarcoidosis AMs and monocytes in normoxic ex vivo culture conditions and without any stimulation exhibit constitutively active HIF-1α and HIF-1β (ARNT) along with its coactivator, p300. Furthermore, in situ HIF-1α immune staining of sarcoidosis lung biopsies demonstrated HIF-1α abundance in the center of granulomatous tissue and in multinucleated giant cells. We found that a higher percentage of CD14^+^ monocytes express HIF-1α and HIF-2α in sarcoidosis subjects as compared to controls. Our data show that the increased HIF-1α expression is coupled to increased Glut1 protein levels, and enhanced IL-1β, IL-6 and IL-17 production. Downregulation of HIF-1α via siRNA or chemical inhibitors in sarcoidosis PBMCs leads to a decrease in IL-6 and IL-17 production at baseline and in response to anti-CD3 stimulation. In sarcoid subjects HIF-2α was predominantly expressed in the lung macrophage population whereas sarcoidosis monocytes showed lower levels of HIF-2α. HIF-2α downregulation had no significant effect on IL-1β and IL-17 production in sarcoidosis (data not shown). We speculate that HIF-2α regulates other macrophage functions such as phagocytosis and cell metabolism. Classically, sarcoidosis granulomas feature activated antigen presenting cells initiating adaptive immune responses with an increase in activated CD4^+^T-cells and Th1 mediated cytokines. Recently, it has been shown that Th17^+^/CD4^+^T cells are increased in sarcoidosis granulomatous tissue and peripheral blood ([@bib12]; [@bib39]; [@bib43]). Recent studies indicated that IL-1β plays a critical role in regulation of Th1/Th17 cells in response to commensal microbes ([@bib11]). IL-1β promotes Th17 differentiation from naive CD4^+^ T cells by enhancing IL-1 receptor expression ([@bib28]). Furthermore, IL-1 synergizes with IL-6 to regulate Th17 differentiation and effector Th17 cell function through regulation of transcription factors, including IRF4 and RORγt ([@bib7]). Thus, in sarcoidosis increased IL-1β and IL-6 explains Th17 differentiation. Previously, our group and other showed increased IL-6 production in AMs and PBMCs of sarcoidosis subjects at baseline and in response to TLR or NLR ligands ([@bib44]; [@bib53]). Levels of IL-6 may be important in progression of fibrotic lung changes in sarcoidosis ([@bib26]). Our data indicate that downregulation of HIF-1α via siRNA or chemical inhibitor reduces IL-6 production by sarcoid PBMCs.

HIF-1α and HIF-2α are two critical transcription factors that regulate an array of genes involved in inflammation, angiogenesis, metabolic reprogramming, mitochondrial function, T-cell differentiation and Th17 development ([@bib9]; [@bib10]; [@bib37]; [@bib40]; [@bib42]). Upregulation of HIF isoform plays a critical role in providing metabolic reprogramming in myeloid cells that is required to develop trained immunity for a robust immune response ([@bib6]). It has been shown that mice with a myeloid cell-specific defect in HIF-1α were unable to mount a trained immune response against bacterial sepsis ([@bib6]; [@bib36]). Trained immunity is associated with profound metabolic reprogramming in macrophages ([@bib69]), dendritic cells, and natural killer cells ([@bib36]). New mounting evidence indicates that metabolic reprogramming, including upregulation of glycolysis and depression of the TCA cycle, is a required metabolic switch for the development of innate memory, which in turn leads to upregulation of inflammatory cytokines including IL-1β and IL-17. Similar to cancer metabolism, during inflammation aerobic glycolysis (Warburg effect) plays an important role in the maintenance of cellular energy supply ([@bib24]; [@bib66]). Sarcoidosis AMs and monocytes exhibit a phenotype resembling the Warburg effect or trained immunity exhibiting an abundance of HIF isoforms, higher expression for Glut1, and higher production of IL-1β and IL-17. Glut1 is regulated by HIF-1α transcriptional activity and its elaboration is an important step in the metabolic switch from oxidative phosphorylation to glycolysis ([@bib5]). Fluorodeoxyglucose positron emission tomography (FDG PET) scans are commonly used to identify metabolic activity in cancer and PET scans have been shown to be useful in active sarcoidosis ([@bib3]; [@bib4]). Increased Glut1 levels may explain the observed increased FDG uptake in PET/CT scans in active sarcoidosis ([@bib52]). Despite the importance of HIF signaling, the role of HIF-1α and HIF-2α in lung diseases has not been established and only a few studies addressed the role of HIFs in primary human immune cells. One previous study reported increased HIF-1α mRNA in lymphocytes of peripheral blood but a decreased mRNA level in HIF-1α BAL cells. In contrast to our study one prior study reported decreased HIF-1α mRNA and protein expression in sarcoidosis tissue biopsies ([@bib62]), although the same study reported increased expression of VEGF, which is directly regulated by HIF ([@bib62]). The discrepancy of the results may be due to stages of the disease or evaluation of heterogeneous cell populations.

Several pathways including the PI3 kinase, mTOR, MEK/ERK, GSK3β, and p38 pathways have been proposed to regulate LPS mediated HIF-1α expression and stabilization ([@bib40]; [@bib41]; [@bib55]; [@bib57]). Previously, we have shown that sustained p38 activation directly controls expression of several cytokines in sarcoid AMs ([@bib44]). The increased p38 phosphorylation in sarcoidosis was associated with lack of mitogen activated protein kinase phosphatase (MKP)-1 expression in sarcoidosis AMs and monocytes ([@bib44]). Furthermore, p38 MAPK regulates IL-17 production by Th17 cells through regulation of various transcription factors ([@bib19]; [@bib38]). Interestingly, our recent study showed that macrophages derived from MKP-1 deficient mice exhibited higher HIF-1α and IL-1β expression and higher ROS production in response to LPS; in addition, p38 inhibition decreased HIF-1α expression in MKP-1 deficient macrophages and modified cytokine production ([@bib55]). In our current work, we found significantly higher HIF-1α expression in sarcoidosis AMs and PBMCs. This can be partly explained by a constitutively active p38 in macrophages of sarcoidosis subjects ([@bib44]; [@bib53]). We observed that a p38 inhibitor (SB203580) partly decreased the expression of HIF-1α (data not shown) and cytokine levels in sarcoidosis.

Activation of TLR4 and TLR2 by a variety of pathogen-derived molecules as well as environmental toxins has been shown to induce and stabilize HIF-1α expression ([@bib14]; [@bib30]; [@bib40]). Abundance of HIF-1α in sarcoidosis also implies aberrant degradation by proteasomal or/and lysosomal pathways. Autophagy and the ubiquitin-proteasome system (UPS) are two major pathways involved in the degradation of proteins. It has been shown that there is a compensatory interaction between these two pathways and inhibition of one pathway leads to activation of the other ([@bib64]). Our RNA sequencing data showed upregulation of lysosomal pathways, confirming previous findings by other investigators ([@bib53]; [@bib61]). LAMP2, along with LAMP1, comprise about 50% of lysosomal proteins. In sarcoidosis we observed upregulation of LAMP2 both at the gene and protein level. CHQ is an ancient drug that in addition to its anti-malaria activity has been used for autoimmune diseases, including sarcoidosis ([@bib34]). Therefore, we determined the effect of CHQ on LAMP2 and HIF-α isoform expression. Surprisingly, we found that CHQ inhibits the increased levels of LAMP2, HIF-α isoforms, and cytokine production in sarcoidosis. We speculate that in sarcoidosis inhibition of lysosomal function by CHQ leads to increased proteasome degradation of HIF-α isoforms leading to subsequent inhibition of IL-1β and IL-17 cytokines production.

Environmental factors, altered metabolism, and inflammation can be linked to epigenetic changes such as methylation and acetylation that may contribute to HIF-1α expression and stability in sarcoidosis ([@bib67]). How HIF signaling in the absence of a hypoxic trigger regulates metabolic reprogramming and influences inflammation in chronic inflammatory diseases, especially respiratory diseases including sarcoidosis, has not been well illuminated. Our report identifies a role for HIF signaling in sarcoidosis granulomatous inflammation. The identification of the mechanisms underlying the aberrant regulation of HIF-1α and HIF-2α leading to persistent inflammation and Th1/Th17 pathology in sarcoidosis should open new avenues in rational drug discovery, not only for this disease but also for other inflammatory diseases.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                          Source or\                           Identifiers                                                                    Additional information
  (species) or\                                                  reference                                                                                                           
  resource                                                                                                                                                                           
  ------------------------- ------------------------------------ ------------------------------------ ------------------------------------------------------------------------------ ------------------------------------
  Genetic reagent           Lipofectamine 2000                   Invitrogen                           Cat. \#11668027                                                                

  Biological sample         Human AMs                            Bronchoalveolar lavage (BAL) cells                                                                                  Sarcoidosis Center, WSU, Detroit,\
                                                                                                                                                                                     USA

  Biological sample         Human PBMCs and monocytes            Heparinized blood                                                                                                   Sarcoidosis Center, WSU, Detroit,\
                                                                                                                                                                                     USA

  Antibody                  HIF-1α (rabbit polyclonal)           Bioss                                RRID:[AB\_](https://scicrunch.org/resolver/AB_)\                               WB (1:500)
                                                                                                      [10857933](https://scicrunch.org/resolver/AB_),\                               
                                                                                                      Cat. \#bs0737                                                                  

  Antibody                  HIF-2α (rabbit polyclonal)           Bioss                                RRID:[AB\_](https://scicrunch.org/resolver/AB_)\                               WB (1:500)
                                                                                                      [10857576](https://scicrunch.org/resolver/AB_), Cat. \#bs1477                  

  Antibody                  ARNT (rabbit monoclonal)             Cell Signaling                       RRID:[AB\_](https://scicrunch.org/resolver/AB_)\                               WB (1:1000)
                                                                                                      [2783880](https://scicrunch.org/resolver/AB_),\                                
                                                                                                      Cat. \# 5531                                                                   

  Antibody                  P300 (rabbit polyclonal)             Santa Cruz Biotechnology             RRID:[AB\_](https://scicrunch.org/resolver/AB_)\                               WB (1:500)
                                                                                                      [2231120](https://scicrunch.org/resolver/AB_),Cat \# sc-585                    

  Antibody                  Glut1 (rabbit polyclonal)            Thermofisher Scientific              RRID:[AB\_](https://scicrunch.org/resolver/AB_)\                               WB (1:1000)
                                                                                                      [2302087](https://scicrunch.org/resolver/AB_),\                                
                                                                                                      Cat \# PA1-46152                                                               

  Antibody                  LAMP2 (mouse monoclonal)             Santa Cruz Biotechnology             RRID:[AB\_](https://scicrunch.org/resolver/AB_)\                               WB (1:1000)
                                                                                                      [626858](https://scicrunch.org/resolver/AB_2305186Cat),Cat \# sc-18822         

  Antibody                  pro-IL-1β (goat polyclonal)          R and D                              Cat \# AF-201-NA                                                               WB (1:1000)

  Antibody                  β-actin (rabbit polyclonal)          Abcam                                RRID:[AB_2305186](https://scicrunch.org/resolver/AB_2305186Cat)Cat \# ab8227   WB (1:1000)

  Antibody                  CD4-FITC (mouse monoclonal)          BD Biosciences                       RRID:[AB_400007](https://scicrunch.org/resolver/AB_400007),Cat \# 340133       

  Antibody                  CD25-PE (mouse monoclonal)           BD Biosciences                       RRID:[AB_400203](https://scicrunch.org/resolver/AB_400203),Cat \# 341009       

  Antibody                  CD14-PerCPCy5.5 (mouse monoclonal)   BD Biosciences                       RRID:[AB_2033939](https://scicrunch.org/resolver/AB_2033939),Cat \# 561116     

  Sequence-based reagent    HIF-1α siRNA, Sense                  GGAACCUGAUGCUUUAACUtt                                                                                               Thermofisher-Scientific

  Sequence-based reagent    HIF-1α siRNA, Anti-sense             AGUUAAAGCAUCAGGUUCCtt                                                                                               Thermofisher-Scientific

  Commercial assay or kit   MTS assay kit\                       Promega\                                                                                                            
                            ELISA kits                           R and D                                                                                                             

  Chemical compound, drug   Chloroquine                          Invivo Gen                           tlrl-chq                                                                       100 mM

  Chemical compound, drug   Echinomycin                          Sigma                                SML0477                                                                        10 nM
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemicals {#s4-1}
---------

Chemicals were purchased from Sigma Chemical (St. Louis, MO) unless specified otherwise. LPS and chloroquine was purchased from InvivoGen (San Diego, CA). Antibodies against HIF-1α (\# bs0737) and HIF-2α (\#bs1477) were purchased from Bioss Inc (Woburn, MA), P300 (sc-585) was from Santa Cruz Biotechnology (Santa Cruz, CA), Glut1 (PA1-46152) from Thermofisher Scientific (Waltham, MA). The antibody for pro-IL-1β (\# AF-201-NA) was purchased from R and D Systems (Minneapolis, MN), and β-actin (\#ab8227) was purchased from Abcam (Cambridge, MA). Horseradish peroxidase--conjugated anti-mouse IgG (\#7076S) and anti-rabbit IgG (\#7074S) antibodies and antibody for ARNT (\#5531) were purchased from Cell Signaling Technology (Beverly, MA). Horseradish peroxidase--conjugated anti-goat IgG (sc-2033) was purchased from Santa Cruz Biotechnology, The anti-human antibodies used for flow cytometry were CD4-FITC (\#340133), CD25-PE (\#341009), CD14-PerCPCy5.5 (\#561116) and purified CD3 (\#555337), purchased from BD Biosciences (San Jose, CA). The secondary antibody used for immunostaining Alexa 488 (\#A11070) was purchased from Molecular Probes (Grand Island, NY). CellTiter 96 AQueous One Solution Cell Proliferation Assay was purchased from Promega (Madison, WI).

Study Design {#s4-2}
------------

The Committee for Investigations Involving Human Subjects at Wayne State University approved the protocol for obtaining alveolar macrophages by bronchoalveolar lavage (BAL) and blood by phlebotomy from control subjects and patients with sarcoidosis. The IRB number for this study is 055208MP4E. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects enrolled for the study. Sarcoidosis diagnosis was based on the ATS/ERS/WASOG statement ([@bib21]). The criteria for enrollment in the diseased group were: (i) a compatible clinical/radiographic picture consistent with sarcoidosis, (ii) histologic demonstration of non-caseating granulomas on the tissue biopsy, and (iii) exclusion of other diseases capable of producing a similar histologic or clinical picture, such as fungus or mycobacteria. Subjects excluded were: (i) smokers, (ii) individuals receiving immune suppressive medication (defined as corticosteroid alone and/or in combination with immune modulatory medications), (iii) individuals with positive microbial culture in routine laboratory examinations or viral infection; or (iv) individuals with known hepatitis or HIV infections or any immune suppressive condition. The criteria for enrollment in the control group were: (i) absence of any chronic respiratory diseases, (ii) lifetime nonsmoker, (iii) absence of HIV or hepatitis infection, and (iv) negative microbial culture. A total of 51 patients with sarcoidosis and 23 controls participated in this study. The medical records of all patients were reviewed, and data regarding demographics, radiographic stages, pulmonary function tests, and organ involvements were recorded.

BAL and the preparation of alveolar macrophages (AMs) {#s4-3}
-----------------------------------------------------

BAL was collected during bronchoscopy after administration of local anesthesia and before tissue biopsies ([@bib44]; [@bib53]). Briefly, a total of 150 to 200 mL of sterile saline solution was injected via fiberoptic bronchoscopy; the BAL fluid was retrieved, measured, and centrifuged. Cells recovered from the BAL fluid were filtered through a sterile gauze pad and washed three times with phosphate-buffered saline (PBS), resuspended in endotoxin-free RPMI 1640 medium (HyClone) supplemented with L-glutamine (Life Technologies), penicillin/streptomycin (Life Technologies), and 1% fetal calf serum (HyClone), and then counted. BAL cells were cultured on adherent plates for 1 hr at 37°C in air containing 5% CO~2~. Non-adherent cells were removed by aspiration; adherent cells were washed three times and used as AMs. Viability of these populations was routinely about 97% and by morphologic criteria the adherent cells were in excess of 99% AMs ([@bib44]; [@bib53]).

Isolation of PBMCs and purification of monocytes {#s4-4}
------------------------------------------------

PBMCs were isolated from heparinized blood using Ficoll-Histopaque (Sigma, St. Louis, MO) density gradient separation followed by washing twice with PBS. Cell suspension was made in endotoxin-free RPMI 1640 medium (HyClone) supplemented with L-glutamine (Life Technologies), penicillin/streptomycin (Life Technologies), and 10% fetal calf serum (HyClone). Cells were cultured in 12-well plates for further experiments ([@bib44]; [@bib53]). CD14^+^ monocytes were purified from PBMCs by using the MACS monocyte isolation kit (Miltenyl Biotech, San Diego, CA) according to the manufacturer's instructions. The purity of enriched monocytes was evaluated by flow cytometry using PerCPCy5.5-conjugated CD14 antibody (\#561116, BD Biosciences); the purity of monocytes was about 95%.

Targeted down regulation of HIF-1α via siRNA {#s4-5}
--------------------------------------------

Isolated AMs or PBMCs were transiently transfected with non-specific silencer siRNA (NS siRNA, 200 pM) or targeted HIF-1α silencer siRNA (200 pM, Thermofisher-Scientific) in the presence of lipofectamine 2000 (Invitrogen). The sequence of siRNA used: sense (5'−3') GGAACCUGAUGCUUUAACUtt and antisense AGUUAAAGCAUCAGGUUCCtt. After 24 hr of transfection, cells were activated with either LPS (100 ng/mL) or anti-CD3 (1 µg/mL). Viability of cells was assessed after siRNA treatment by MTS assay and 95% of cells were viable.

Cell viability {#s4-6}
--------------

Cell viability was assessed using MTS assay \[CellTiter 96 AQueous One Solution Cell Proliferation Assay\] (Promega, Madison, WI) following the manufacturer's instructions. Briefly, cells equivalent to 1 × 10^4^/well were seeded in 96-well culture plate and incubated for 24--48 hr with different treatments. After incubation, 20 µl of CellTiter 96 AQueous One Solution Reagent was added per well for 2 hr and the absorbance was measured at 490 nm using a 96-well plate reader.

Enzyme- Linked Immunosorbent Assay (ELISA) {#s4-7}
------------------------------------------

The levels of IL-1β, IL-1Ra, IL-17, IL-10, IL-6, and IFN-γ in the conditioned medium were measured by ELISA according to the manufacturer\'s instructions (ELISA DuoKits; R and D Systems, Minneapolis, MN).

Flow cytometry and cell surface immunostaining {#s4-8}
----------------------------------------------

PBMCs from subjects with sarcoidosis were isolated, cultured, and after appropriate treatment were stained for cell surface markers using fluorescent labelled antibodies for CD4-FITC (\#340133, BD Biosciences), and CD25-PE (\#341009, BD Biosciences). Intracellular staining of PBMCs was done for HIF-1α and HIF-2α. Briefly, PBMCs were first surface stained for CD14 using CD14-PerCPCy5.5 antibody and then fixed using 100 μl of 1% paraformaldehyde for 30 min and then permeabilized with permeabilization buffer (0.5% saponin) for 15 min at room temperature. Cells were centrifuged and resuspended in 100 μl of permeabilization buffer and stained with HIF-1α (bs0737, Bioss Inc) or HIF-2α (bs1477, Bioss Inc) antibody for 30 min. Cells were washed and stained with the Alexa 488 secondary antibody (\#A11070, Molecular Probes). After 30 min cells were washed twice, resuspended in staining buffer, and analyzed for CD14^+^HIF-1α^+^ and CD14+HIF-2α^+^ monocytes by flow cytometry. PBMCs were not stained specifically to exclude DC contamination. Flow cytometry was performed on a BD LSR II SORP and data analysis was performed using FlowJo software (FlowJo, LLC, Ashland, OR) ([@bib53]). Samples were gated on cells using FSC/SSC and doublet discrimination was performed to identify singlets using SSC-W vs. SSC-A. The flowcytometry work was done at the Microscopy, Imaging and Cytometry Resources (MICR) Core at the Karmanos Cancer Institute, Wayne State University.

Immunofluorescent staining {#s4-9}
--------------------------

Intracellular expression of HIF-1α in sarcoidosis AMs was visualized by immunofluorescence staining. AMs (1 × 10^5^) were allowed to adhere overnight on chamber slides. The cells were washed briefly with PBST and fixed with 3.7% paraformaldehyde. Cells were washed and permeabilized with 0.1% Triton X-100, blocked (10% FCS), and then incubated with anti-HIF-1α (bs0737,Bioss Inc) overnight at 4°C. The secondary antibody used was Alexa-fluor 488- conjugated goat anti-rabbit antibody. The next day cells were washed three times with PBS for 5 min, the slide was mounted with a drop of ProLong Gold antifade reagent with DAPI (Invitrogen). The slide was examined using an Axiovert 40 CFL fluorescence microscope (Carl Zeiss MicroImaging, Inc).

Protein extraction and immunoblotting {#s4-10}
-------------------------------------

Total cellular proteins were extracted by addition of RIPA buffer containing a protease inhibitor cocktail and antiphosphatase I and II (Sigma Chemicals). Protein concentration was measured with the BCA assay (Thermo Scientific, CA). Equal amounts of proteins (10--25 μg) were mixed 1/1 (v/v) with 2x sample buffer (20% glycerol, 4% sodium dodecyl sulfate, 10% 2-βME, 0.05% bromophenol blue, and 1.25 M Tris-HCl, pH 6.8), and fractionated on a 10% sodium dodecyl sulfate--polyacrylamide gel. Proteins were transferred onto a polyvinylidene difluoride membrane (Bio-Rad) for 60 min at 18 V using a SemiDry Transfer Cell (Bio-Rad). The polyvinylidene difluoride membrane was blocked with 5% nonfat dry milk in TBST (Tris-buffered saline with 0.1% Tween 20) for 1 hr, washed, and incubated with primary Abs (1/1000) overnight at 4°C. The blots were washed with TBST and then incubated for 1 hr with horseradish peroxidase--conjugated secondary anti-IgG Ab using a dilution of 1/10,000 in 5% nonfat dry milk in TBST. Membranes were washed four times in TBST. Immuno-reactive bands were visualized with a chemiluminescent reagent (Amersham GE, PA). Images were captured on Hyblot CL film (Denville; Scientific, Inc; Metuchen, NJ) using a JPI automatic X-ray film processor model JP-33. Optical density analysis of signals was performed using Image J software ([@bib44]; [@bib53]).

Immunohistochemistry {#s4-11}
--------------------

Tissue sections from the sarcoidosis transbronchial lung biopsy samples were selected for immunostaining after review of the glass slides that had been previously prepared using the routine hematoxylin-eosin protocol on paraffin-embedded sections. Additional fixed slides were cut, subjected to peroxide block protocol, pretreated, and then incubated first with primary antibody (anti-HIF-1α, bs0737, Bioss Inc ) and then with a secondary conjugated polymer; each incubation step was done for 30 min at room temperature. Negative staining was done by using an isotype control antibody. After another incubation step with the chromogen (5 min at room temperature), the sections were counterstained with hematoxylin and dehydrated with ethanol and xylene prior to mounting. Images were analyzed by microscopy (BX40, Olympus).

Statistical Analyses {#s4-12}
--------------------

A Student *t-test* or one-way analysis of variance and *post hoc* repeated measure comparisons (least significant difference) were performed to identify differences between groups. ELISA results were expressed as mean ± SEM. For all analyses, two-tailed *p* values of less than 0.05 were considered to be significant.
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Thank you for submitting your article \"HIF-1α Regulates IL-1β and IL-17 in Sarcoidosis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Jos WM van der Meer as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Siroon Bekkering (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a well-executed study showing a key role for unregulated HIF-1α in the pro-inflammatory cytokine response in sarcoidosis. Mechanistic studies in sarcoidosis are definitely needed, since the understanding of the pathogenesis is still rather limited. The clinical material used, the experiments both in alveolar macrophages and in peripheral monocytes are adequate and convincing, also because of the inhibition studies performed.

Essential revisions:

1\) The authors assert that, to the best of their knowledge, this is the first report to interrogate the role of HIF in sarcoidosis. Whilst this is the most comprehensive, and likely a more robust study to look at the function of HIF in the disease, there are two other reports detailing HIF expression in sarcoidosis (Tzouvelekis et al., 2012 and Piotrowski et al., 2015). One of these studies conflicts with the finding of HIF granuloma expression presented here in this report, therefore it would be of value to discuss these within this paper and provide possible reasons for the differences or similarities in findings.

2\) Regarding flow cytometry, the authors show HIF-1α expression in CD14^+^ cells. They should FSC and SSC gating and acknowledge DC contamination, if that has not been dealt with.

3\) The conclusion drawn from flow cytometry data for PBMCs makes reference to increased CD14^+^HIF-1α^+^monocytes in the patient samples, stating that this is 5-9% in controls and 20-35% in sarcoidosis patient samples. This is misleading, as monocytes make up a higher percentage of PBMCs in sarcoidosis. It is suggested that this be reworded to represent HIF^+^ percentage of monocytes, and that quantitative figures provided for all donors along with degree of expression (MFI or equivalent).

4\) For Figure 3, a negative antibody control staining is necessary to support the conclusion, as macrophages and giant cells display high non-specific staining. This is important for validation in light of point 1.

5\) The authors show single cell examples of confocal microscopic studies. The question is are all cells showing this upregulated pattern? A remark on this would be helpful.

6\) The authors say that they have observed similar results on liver and skin samples (subsection "Confocal microscopy of sarcoidosis AMs and immunohistochemistry of sarcoidosis tissues confirmed increased HIF-1α expression and its nuclear accumulation"). This is a bit too loose. How many samples? What does \'similar\' exactly mean?

7\) In Figure 4, why were the cells not stimulated by LPS and why was only baseline expression measured? In Figure 5, the expression is measured after stimulation and it might be interesting to look at secreted IL-1β after stimulation in Figure 4 as well. Furthermore, in Figure 5C, the expression of pro-IL-1β (unstimulated pro-IL-1β) should be similar to the expression in Figure 4 (as it is the same measurement) but suddenly looks much lower. Why is this?

8\) Was the viability of the cells checked after siRNA treatment? Primary cells usually don\'t like siRNA treatment and die. Please add proof of viability.

9\) In Figure 6B, the expression of IL-10 looks decreased. There is no statistical significance (as is hard to obtain with n=4 generally), but the same trend is seen in Figure 6A. What would happen if one would increase it to n=6, would that become statistically significant? Will that change the conclusions?

10\) In discussing the specificity of HIF for IL-17 and IL-1β, the data shows an impact on IL-6 also. Additionally, in discussions, the lack of significant impact on IFN-γ is noted but not considered of importance. IL-6 and IFN-γ are notably important cytokines in sarcoidosis, both being overexpressed in granulomatous tissue, so addressing these findings would be useful for wider context.

11\) In the text explaining Figure 7A, it is mentioned that patients' PBMCs have a higher expression of CD4^+^CD25^+^ cells. But higher than what? There are no control PBMCs included in this analysis, is that correct? Why not? What is the baseline expression in control PBMCs?

12\) The findings of sustained enhanced (spontaneous) IL-1 production and upregulated HIF-1α are reminiscent of the trained immunity state of mononuclear phagocytes, in which the metabolic shift (Warburg effect) and epigenetic reprogramming are tightly connected (see Cheng et al., 2014). This should be discussed.

13\) When IL-1β production is enhanced, the net biological effect is often dependent on the production level of IL-1Ra. If the investigators still have supernatants, it would be of interest to see whether IL-1Ra is also unregulated.

14\) A main criticism is the Discussion. This section could be much better structured and written, as the reviewers lost track of the authors\' findings in their reasoning. Please start with a few sentences telling the key findings of this work, and put that into the perspective of what is known about this in sarcoidosis and in general. Thereafter, please go into the minor findings, to end with future perspectives (and speculate about the clinical implications of these very interesting findings).

15\) In the Discussion, two interesting results of inhibitors used are mentioned with \'data not shown\'. Why are these data not included in the manuscript? This would add some interesting pathway information to the story. It is preferable not to mention unpublished data, if at all possible.
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\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"HIF-1α Regulates IL-1β and IL-17 in Sarcoidosis\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Tadatsugu Taniguchi as the Senior Editor, and by Jos WM van der Meer as the Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) The rebuttal to our major criticism 1 deserves a little more discussion. The rebuttal is quite OK but too little of it reached the revised manuscript. So please also incorporate the discrepancies with the Piotrowski paper.

2\) The figure presented in the rebuttal to our criticism \#6 merits to be added as a supplementary figure with a short(er) description of the case in the legend.

3\) The rebuttal under criticism \#9 should also be reflected in the revision.

4\) Give the full reference for the Avril paper.

10.7554/eLife.44519.026

Author response

> Essential revisions:
>
> 1\) The authors assert that, to the best of their knowledge, this is the first report to interrogate the role of HIF in sarcoidosis. Whilst this is the most comprehensive, and likely a more robust study to look at the function of HIF in the disease, there are two other reports detailing HIF expression in sarcoidosis (Tzouvelekis et al., 2012 and Piotrowski et al., 2015). One of these studies conflicts with the finding of HIF granuloma expression presented here in this report, therefore it would be of value to discuss these within this paper and provide possible reasons for the differences or similarities in findings.

We were aware of these two publications. Both studies evaluated predominantly HIF-1α mRNA levels using PCR. Tzouvelekis et al. reported decreased expression of HIF-1α mRNA and protein in tissue biopsies. The tissue presented in that manuscript appears to show advanced fibrotic changes with complete destruction of lung structures. Furthermore, they show upregulation of VEGF expression. Increased VEGF expression indicates increased HIF-1α activity as VEGF is highly regulated by HIF-1α. The discrepancy between our results and their findings could be due to sampling of biopsy at different stages of the disease or treatment effect. Note that in our study, most of the patients were recruited before starting any drug treatment. Furthermore, similar to their results our RNA-Seq data didn't show any differential expression of HIF-1α between healthy controls and sarcoid patients. We mentioned that pathway analysis indicated upregulation of metabolic pathways that are regulated by HIF pathways. The study done by Piotrowski et al. was concluded that the upregulation of HIF-1α and VEGF in PBMCs of sarcoid patients was associated with poor lung function. We were unable to access the complete paper of Piotrowski. Reading the Abstract, it is not clear to us what cell type they analyzed (blood lymphocytes versus BAL?). Hence, we are unsure how those results compare to our findings.

> 2\) Regarding flow cytometry, the authors show HIF-1α expression in CD14^+^ cells. They should FSC and SSC gating and acknowledge DC contamination, if that has not been dealt with.

As suggested, we have shown the FSC and SSC gating in Figure 2J. We acknowledge that we did not do any staining to exclude DCs. For flowcytometry, PBMCs were double stained with CD14 and HIF-1α antibodies. The upper right quadrant shows CD14^+^HIF-1α^+^ cells that are CD14^+^monocytes expressing HIF-1α. We added a sentence indicating that we did not specifically assess for DCs.

> 3\) The conclusion drawn from flow cytometry data for PBMCs makes reference to increased CD14^+^HIF-1α^+^monocytes in the patient samples, stating that this is 5-9% in controls and 20-35% in sarcoidosis patient samples. This is misleading, as monocytes make up a higher percentage of PBMCs in sarcoidosis. It is suggested that this be reworded to represent HIF^+^ percentage of monocytes, and that quantitative figures provided for all donors along with degree of expression (MFI or equivalent).

We agree with the comment. We have reworded in the Results and legend sections to accommodate your suggestion, however we also think it important to mention double positivity of CD14 and HIF-1α.

The percentage of CD14^+^HIF-1α^+^monocytes obtained from the donors used for the study are shown in [Author response image 1](#respfig1){ref-type="fig"}.

![](elife-44519-resp-fig1){#respfig1}

> 4\) For Figure 3, a negative antibody control staining is necessary to support the conclusion, as macrophages and giant cells display high non-specific staining. This is important for validation in light of point 1.

It is our opinion that the best control is the unaffected appearing lung tissue of the same subject. However, we added the negative (isotype control) staining as suggested in Figure 3K.

> 5\) The authors show single cell examples of confocal microscopic studies. The question is are all cells showing this upregulated pattern? A remark on this would be helpful.

Thank you for your comments. The purpose of performing confocal microscopy of single cells was to identify whether HIF-1α is present in the nuclei, suggesting transcriptional activity of HIF-1α. Furthermore, due to the fact that we worked with precious human samples, and we could not perform fractionation of nuclear proteins (due to limited number of cells), we performed confocal microscopy instead. Based on the reviewer's suggestion we performed regular immunofluorescent microscopy and quantitated the percentage of cells showing HIF-1α expression. It shows that about 60-90% of AMs show HIF-1α expression. We added a representative section of DAPI and HIF-1α in Figure 3.

> 6\) The authors say that they have observed similar results on liver and skin samples (subsection "Confocal microscopy of sarcoidosis AMs and immunohistochemistry of sarcoidosis tissues confirmed increased HIF-1α expression and its nuclear accumulation"). This is a bit too loose. How many samples? What does \'similar\' exactly mean?

We assessed HIF-1α expression in two skin and two liver biopsies. In one liver biopsy, we noticed high HIF-1 a staining in granulomatous tissue and surrounding hepatocytes. This patient is a young woman (28 year old), who at 21 years of age developed sarcoidosis. She has severe multiorgan involvement, including lungs, eyes and heart' as well as liver. Due to sarcoidosis uveitis she is now legally blind. She had very abnormal liver function tests. The purpose of performing a liver biopsy was to assess for her abnormal liver function tests. H&E staining showed severe granulomatous inflammation. There were extensive increased HIF-1α expression throughout the liver. While negative staining did not show non-specific staining. Therefore, we believe that increased HIF-1α staining in the hepatocytes may represent a true increased of HIF-1α associated with the severity of disease in this patient. We have now added Figure 3---figure supplement 1 in the final version to show there are multiple granulomas in the liver with increased mononuclear cell infiltrates. Yet, no significant fibrosis is seen in the H&E staining.

> 7\) In Figure 4, why were the cells not stimulated by LPS and why was only baseline expression measured? In Figure 5, the expression is measured after stimulation and it might be interesting to look at secreted IL-1β after stimulation in Figure 4 as well.

In Figure 4, we are showing the comparison between the baseline levels of pro- IL-1β between sarcoid patients and healthy controls. Therefore, we selected the unstimulated samples of patients and controls. As suggested by the reviewers we have added the data for secreted IL-1β with LPS stimulation in revised Figure 4F and 4G.

> Furthermore, in Figure 5C, the expression of pro-IL-1β (unstimulated pro-IL-1β) should be similar to the expression in Figure 4 (as it is the same measurement) but suddenly looks much lower. Why is this?

Figure 5C and Figure 4, Western blots are generated from different patient samples. As such, these are different biological replicates and not from the same subject. In Figure 5C, we used the lower exposure blot to show the changes in the pro-IL-1β levels after LPS stimulation and HIF-1α siRNA treatment. [Author response image 2](#respfig2){ref-type="fig"} is the Western blot of the same samples with higher exposure.
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> 8\) Was the viability of the cells checked after siRNA treatment? Primary cells usually don\'t like siRNA treatment and die. Please add proof of viability.

We usually assess cell viability in multiple ways after each experiment: (1) inspection by light microscopy, (2) trypan blue staining, and (3) MTT or MTS assay. The viability of the cells after siRNA treatment was determined by MTS assay (Promega). Both the AMs and PBMCs were viable after the siRNA treatment as shown in [Author response image 3](#respfig3){ref-type="fig"}.
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> 9\) In Figure 6B, the expression of IL-10 looks decreased. There is no statistical significance (as is hard to obtain with n=4 generally), but the same trend is seen in Figure 6A. What would happen if one would increase it to n=6, would that become statistically significant? Will that change the conclusions?

We agree that in Figure 6B, IL-10 trends to be lower after treatment of PBMCs with HIF-1α siRNA, although not statistically significant. Similarly, in Figure 5 the treatment of AMs with HIF-1α siRNA didn't show a statistically significant decrease in IL-10. We agree that both Interferon and IL-10 show a trend to lower levels, which can be due to paracrine IL-1β function.

> 10\) In discussing the specificity of HIF for IL-17 and IL-1β, the data shows an impact on IL-6 also. Additionally, in discussions, the lack of significant impact on IFN-γ is noted but not considered of importance. IL-6 and IFN-γ are notably important cytokines in sarcoidosis, both being overexpressed in granulomatous tissue, so addressing these findings would be useful for wider context.

Thank you for the comment. Our current results show the co-regulation of IL-1β and IL-6 confirming our previous published results in sarcoidosis (Talreja et al., 2016). In this manuscript, we chose to be focused on IL-1β and IL-17. Based on reviewers' suggestion we added a sentence to this fact.

> 11\) In the text explaining Figure 7A, it is mentioned that patients' PBMCs have a higher expression of CD4^+^CD25^+^ cells. But higher than what? There are no control PBMCs included in this analysis, is that correct? Why not? What is the baseline expression in control PBMCs?

We agree with reviewers that in the text we should mention the baseline expression of CD4^+^CD25^+^ cells in control and sarcoid PBMCs. In fact, we have analyzed 23 PBMCs samples from sarcoid patients and 7 samples from healthy controls. The range of baseline expression of CD4^+^CD25^+^ cells in control PBMCs is about 1-5% whereas in sarcoid patients it is about 2-25%.

After reviewing our data, we would like to replace the previous figure with results of a different patient, which is more representative of the study group. Therefore, we added a new Figure 7A-D, as this is more representative of sarcoidosis subjects.

In response to your question, we would like to provide a box plot of CD4^+^CD25^+^ cells in control and sarcoid PBMCs obtained using flowcytometry. In the revised manuscript, we have provided these data in the Results section.

![](elife-44519-resp-fig4){#respfig4}

> 12\) The findings of sustained enhanced (spontaneous) IL-1 production and upregulated HIF-1α are reminiscent of the trained immunity state of mononuclear phagocytes, in which the metabolic shift (Warburg effect) and epigenetic reprogramming are tightly connected (see Cheng et al., 2014). This should be discussed.

We added that in the Discussion.

> 13\) When IL-1β production is enhanced, the net biological effect is often dependent on the production level of IL-1Ra. If the investigators still have supernatants, it would be of interest to see whether IL-1Ra is also unregulated.

We agree with the reviewers that it is interesting to see whether IL-1Ra is also unregulated when IL-1β production is enhanced. As suggested, we have measured levels of IL-1Ra via ELISA in the supernatants of cultured AMs and PBMCs from patients and controls samples. We included IL-1Ra data in revised Figure 4H and 4I. Although, several previous studies have already reported increased IL-1Ra in sarcoidosis.

> 14\) A main criticism is the Discussion. This section could be much better structured and written, as the reviewers lost track of the authors\' findings in their reasoning. Please start with a few sentences telling the key findings of this work, and put that into the perspective of what is known about this in sarcoidosis and in general. Thereafter, please go into the minor findings, to end with future perspectives (and speculate about the clinical implications of these very interesting findings).

We are thankful to reviewers for their valuable suggestions. We have revised the Discussion accordingly.

> 15\) In the Discussion, two interesting results of inhibitors used are mentioned with \'data not shown\'. Why are these data not included in the manuscript? This would add some interesting pathway information to the story. It is preferable not to mention unpublished data, if at all possible.

We eliminated the statement regarding dual IRAK1/4 and RIP2 inhibitor. We previously reported the importance of p38 activation in sarcoidosis. Similarly, we and other groups have shown that p38 inhibitor decreases the level of HIF-1α. We felt we should connect this result with our previous finding, but we did not see any novelty to provide the data.

> \[Editors\' note: further revisions were requested prior to acceptance, as described below.\]
>
> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) The rebuttal to our major criticism 1 deserves a little more discussion. The rebuttal is quite OK but too little of it reached the revised manuscript. So please also incorporate the discrepancies with the Piotrowski paper.

We expanded the discussion about these two manuscripts.

> 2\) The figure presented in the rebuttal to our criticism \#6 merits to be added as a supplementary figure with a short(er) description of the case in the legend.

We added the liver biopsy result in Figure 3---figure supplement 1, with description.

> 3\) The rebuttal under criticism \#9 should also be reflected in the revision.

This is added in the Discussion.

> 4\) Give the full reference for the Avril paper.

It is now provided.
